Indolactam and benzolactam compounds as new medicinal leads with binding selectivity for C1 domains of proteins kinase C isozymes

Current Pharmaceutical Design

Volumn 10, Issue 12, 2004, Pages 1371-1385

  Irie, Kazuhiro ^a   Nakagawa, Yu ^a   Ohigashi, Hajime ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Benzolactam; Diacylglycerol kinase; Indolactam; Phorbol ester; Protein kinase C

Indexed keywords

AMIDE; BENZOLACTAM; BRYOSTATIN; BRYOSTATIN 1; CARBONYL DERIVATIVE; DIACYLGLYCEROL; DIACYLGLYCEROL KINASE; HYDROGEN; INDOLACTAM; INDOLACTAM V; INGENOL; INGENOL 3 BENZOATE; ISOENZYME; LACTAM DERIVATIVE; LACTONE DERIVATIVE; LIGAND; OXYGEN; PEPTIDE LIBRARY; PHORBOL DIBUTYRATE; PHORBOL ESTER; PROTEIN KINASE C; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C GAMMA; RESINIFERONOL; TUMOR PROMOTER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING AFFINITY; BINDING SITE; DRUG BINDING; DRUG CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; BENZODIAZEPINONES; DRUG DELIVERY SYSTEMS; HUMANS; INDOLES; ISOENZYMES; LACTAMS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN KINASE C; PROTEIN STRUCTURE, TERTIARY;

EID: 2342439577     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384907     Document Type: Review

References (94)

1. Fujiki H, Sugimura T. New classes of tumor promoters: teleocidin, aplysiatoxin, and palytoxin. Adv Cancer Res 1987; 49: 223-64.
2. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982; 257: 7847-51.
3. Fujiki H, Tanaka Y, Miyake R, Kikkawa U, Nishizuka Y, Sugimura T. Activation of calcium-activated, phospholipid-dependent protein kinase (protein kinase C) by new classes of tumor promoters: teleocidin and debromoaplysiatoxin. Biochem Biophys Res Commun 1984; 120: 339-43.
4. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 1984; 308: 693-8.
5. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9: 484-96.
6. Hurley JH, Newton AC, Parker PJ, Blumberg PM, Nishizuka Y. Taxonomy and functions of C1 protein kinase C homology domains. Protein Sci 1997; 6: 477-80.
7. Kazanietz MG, Areces LB, Bahador A, Mischak H, Goodnight J, Mushinski JF, et al. Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol 1993; 44: 298-307.
8. Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y. Protein kinase C ζ subspecies from rat brain: its structure, expression, and properties. Proc Natl Acad Sci USA 1989; 86: 3099-103.
9. 1, an atypical isoform of protein kinase C derived from insulin-secreting cells. J Biol Chem 1993; 268: 24296-302.
10. Akimoto K, Mizuno K, Osada S, Hirai S, Tanuma S, Suzuki K, et al. A new member of the third class in the protein kinase C family, PKCλ, expressed dominantly in an undifferentiated mouse embryonal carcinoma cell line and also in many tissues and cells. J Biol Chem 1994; 269: 12677-83.
11. Szallasi Z, Bögi K, Gohari S, Biro T, Acs P, Blumberg PM. Non-equivalent roles for the first and second zinc fingers of protein kinase Cδ. J Biol Chem 1996; 271: 18299-301.
12. Hunn M, Quest AFG. Cysteine-rich regions of protein kinase Cδ are functionally non-equivalent. FEBS Lett 1997; 400: 226-32.
13. Ananthanarayanan B, Stahelin RV, Digman MA, Cho W. Activation mechanisms of conventional protein kinase C isoforms are determined by the ligand affinity and conformational flexibility of their C1 domains. J Biol Chem 2003; 278: 46886-94.
14. Geiger T, Müller M, Dean NM, Fabbro D. Antitumor activity of a PKCα antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anti-Cancer Drug Design 1998; 13: 35-45.
15. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKCβ inhibitor. Science 1996; 272: 728-31.
16. Malmberg AB, Chen C, Tonegawa S, Basbaum AI. Preserved acute pain and reduced neuropathic pain in mice lacking PKCγ. Science 1997; 278: 279-83.
17. Ono Y, Fujii T, Igarashi K, Kuno T, Tanaka C, Kikkawa U, et al. Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence. Proc Natl Acad Sci USA 1989; 86: 4868-71.
18. Burns DJ, Bell RM. Protein kinase C contains two phorbol ester binding domains. J Biol Chem 1991; 266: 18330-38.
19. Wender PA, Irie K, Miller BL. Identification, activity, and structural studies of peptides incorporating the phorbol ester-binding domain of protein kinase C. Proc Natl Acad Sci USA 1995; 92: 239-43.
20. Irie K, Oie K, Nakahara A, Yanai Y, Ohigashi H, Wender PA, et al. Molecular basis for protein kinase C isozyme-selective binding: the synthesis, folding, and phorbol ester binding of the cysteine-rich domains of all protein kinase C isozymes. J Am Chem Soc 1998; 120: 9159-67.
21. Fukuda H, Irie K, Nakahara A, Ohigashi H, Wender PA. Solid-phase synthesis, mass spectrometric analysis of the zinc-folding, and phorbol ester-binding studies of the 116-mer peptide containing the tandem cysteine-rich C1 domains of protein kinase C gamma. Bioorg Med Chem 1999; 7: 1213-21.
22. Yajima H, Fujii N. Totally synthetic crystalline ribonuclease A. Biopolymers 1981; 20: 1859-67.
23. Schneider J, Kent SBH. Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease. Cell, 1988; 54: 363-8.
24. Nishiuchi Y, Inui T, Nishio H, Bódi J, Kimura T, Tsuji FI, et al. Chemical synthesis of the precursor molecule of the Aequorea green fluorescent protein, subsequent folding, and development of fluorescence. Proc Natl Acad Sci USA 1998; 95: 13549-54.
25. Carpino LA. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. J Am Chem Soc 1993; 115: 4397-8.
26. Shindo M, Irie K, Nakahara A, Ohigashi H, Konishi H, Kikkawa U, et al. Toward the identification of selective modulators of protein kinase C (PKC) isozymes: establishment of a binding assay for PKC isozymes using synthetic C1 peptide receptors and identification of the critical residues involved in the phorbol ester binding. Bioorg Med Chem 2001; 9: 2073-81.
27. Hubbard SR, Bishop WR, Krischmeier P, George SJ, Cramer SP, Hendrickson WA. Identification and characterization of zinc binding sites in protein kinase C. Science 1991; 254: 1776-9.
28. Quest AFG, Bloomenthal J, Bardes ESG, Bell RM. The regulatory domain of protein kinase C coordinates four atoms of zinc. J Biol Chem 1992; 267: 10193-7.
29. Hommel U, Zurini M, Luyten M. Solution structure of a cysteine-rich domain of rat protein kinase C. Nat Struct Biol 1994; 1: 383-7.
30. Ichikawa S, Hatanaka H, Takeuchi Y, Ohno S, Inagaki F. Solution structure of cysteine-rich domain of protein kinase Cα. J Biochem 1995; 117: 566-74.
31. Xu RX, Pawelczyk T, Xia TH, Brown SC. NMR structure of a protein kinase C-γ phorbol-binding domain and study of protein-lipid micelle interactions. Biochemistry 1997; 36: 10709-17.
32. Zhang G, Kazanietz MG, Blumberg PM, Hurley JH. Crystal structure of the Cys2 activator-binding domain of protein kinase Cδ in complex with phorbol ester. Cell 1995; 81: 917-24.
33. Freemont PS. The RING finger. A novel protein sequence motif related to the zinc finger. Ann N Y Acad Sci 1983; 684: 174-92.
34. Shindo M, Irie K, Fukuda H, Ohigashi H. Analysis of the non-covalent interaction between metal ions and the cysteine-rich domain of protein kinase C eta by electrospray ionization mass spectrometry. Bioorg Med Chem 2003; 11: 5075-82.
35. 3H]phorbol 12,13-dibutyrate binding. Cancer Res 1985; 45: 19-24.
36. Irie K, Nakahara A, Ohigashi H, Fukuda H, Wender PA, Konishi H, et al. Synthesis and phorbol ester-binding studies of the individual cysteine-rich motifs of protein kinase D. Bioorg Med Chem Lett 1999; 9: 2487-90.
37. Irie K, Ohigashi H. Synthesis and functional analysis of the cysteine-rich domains of protein kinase C (PKC) for development of new medicinal leads with PKC isozyme and C1 domain selectivity (in Japanese). J Syn Org Chem Japan 2002; 60: 563-72
38. Irie K, Ohigashi H. Functional analysis of the phorbol ester receptors by peptide synthesis (in Japanese). Kagaku to Seibutsu 2004; 42: 54-62.
39. Wender PA, Lippa B, Park CM, Irie K, Nakahara A, Ohigashi H. Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes. Bioorg Med Chem Lett 1999; 9: 1687-90.
40. Irie K, Nakahara A, Ikawa Y, Tanaka M, Nakagawa Y, Nakamura Y, et al. Synthesis and tumor-promoting activities of 12-epiphorbol 12,13-dibutyrate. Biosci Biotechnol Biochem 2000; 64: 2429-36.
41. Irie K, Nakahara A, Nakagawa Y, Ohigashi H, Shindo M, Fukuda H, et al. In: Shioiri T. Ed, Peptide Science 2000. Nagoya, The Japanese Peptide Society, 2001; 197-200
42. Irie K, Nakahara A, Nakagawa Y, Ohigashi H, Shindo M, Fukuda H, et al. Establishment of a binding assay for protein kinase C isozymes using synthetic C1 peptides and development of new medicinal leads with protein kinase C isozyme and C1 domain selectivity. Pharmacol Ther 2002; 93: 271-81.
43. Hergenhahn M, Adolf W, Hecker E. Resiniferatoxin and other esters of novel polyfunctional diterpenes from Euphorbia resinifera and unispina. Tetrahedron Lett 1975; 16: 1595-8.
44. Mori T, Takai Y, Yu B, Takahashi J, Nishizuka Y, Fujikura T. Specificity of the fatty acyl moieties of diacylglycerol for the activation of calcium-activated, phorpholipid-dependent protein kinase. J Biochem 1982; 91: 427-31.
45. Pettit GR, Herald CL, Doubek DL, Herald DL. Isolation and structure of bryostatin 1. J Am Chem Soc 1982; 104: 6846-8.
46. Reddig PJ, Dreckschimdt NE, Ahrens H, Simsiman R, Tseng CP, Zou J, et al. Transgenic mice overexpressing protein kinase Cδ in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1999; 59: 5710-8.
47. Reddig PJ, Dreckschmidt NE, Zou J, Bourguignon SE, Oberley TD, Verma AK. Transgenic mice overexpressing protein kinase Cε in their epidermis exhibit reduced papilloma burden but enhanced carcinoma formation after tumor promotion. Cancer Res 2000; 60: 595-602.
48. Chida K, Hara T, Hirai T, Konishi C, Nakamura K, Nakao K, et al. Disruption of protein kinase Cη results in impairment of wound healing and enhancement of tumor formation in mouse skin carcinogenesis. Cancer Res 2003; 63: 2404-8.
49. Irie K, Hirota M, Hagiwara N. Koshimizu K, Hayashi H, Murao S, et al. The Epstein-Barr virus early antigen inducing indole alkaloids, (-)-indolactam V and its related compounds produced by Actinomycetes. Agric Biol Chem 1984; 48: 1269-74.
50. Endo Y, Shudo K, Okamoto T. Molecular requirements for epigenetic modulators. Synthesis of active fragments of teleocidins and lyngbyatoxin. Chem Pharm Bull 1982; 30: 3457-60.
51. Irie K, Koshimizu K. Structure-activity studies of indole alkaloid tumor promoters. Mem Coll Agric Kyoto Univ 1988; 132: 1-59.
52. Endo Y, Ohno M, Shudo K. Active conformation of teleocidins: design and synthesis of new active compounds (in Japanese). Yakugaku Zasshi 1994; 114: 464-77.
53. Irie K, Koshimizu K. In: Chu, CK and Cutler, HG Ed, Natural Products as Antiviral Agents. New York, Plenum Press, 1992; 257-73.
54. Irie K, Koshimizu K. Chemistry of indole alkaloid tumor promoter teleocidins. Comments Agric Food Chem 1993; 3: 1-25.
55. Nakagawa Y, Irie K, Nakamura Y, Ohigashi H. Synthesis and biological activities of (-)-6-n-octyl-indolactam-V, a new potent analogue of the tumor promoter (-)-indolactam-V. Biosci Biotechnol Biochem 1998; 62: 1568-73.
56. Irie K, Hagiwara N, Tokuda H, Koshimizu K. Structure-activity studies of the indole alkaloid tumor promoter teleocidins. Carcinogenesis 1987; 8: 547-52.
57. Hirota M, Suganuma M, Yoshizawa S, Horiuchi T, Nakayasu M, Hasegawa M, et al. Synthetic analogues (indolactams) of (-)-indolactam-V are new congeners of the teleocidin class of tumor promoters. Jpn J Cancer Res (Gann) 1987; 78: 577-82.
58. Irie K, Okuno S, Kajiyama S, Koshimizu K, Nishino H, Iwashima A. Quantitative structure-activity studies on indole alkaloid tumor promoter indolactam congeners. Carcinogenesis 1991; 12: 1883-6.
59. Fujiki H, Suganuma M, Nakayasu M, Tahira T, Endo Y, Shudo K, et al. Structure-activity studies on synthetic analogues (indolactams) of the tumor promoter teleocidin. Jpn J Cancer Res (Gann) 1984; 75: 866-70.
60. Endo Y, Shudo K, Itai A, Hasegawa M, Sakai S. Synthesis and stereochemistry of indolactam-V, an active fragment of teleocidins. Structural requirements for tumor-promoting activity. Tetrahedron 1986; 42: 5905-24.
61. Irie K, Koizumi F, Iwata Y, Ishii T, Yanai Y, Nakamura Y, et al. Synthesis and biological activities of new conformationally fixed analogues of (-)-indolactam-V, the core structure of tumor-promoting teleocidins. Bioorg Med Chem Lett 1995; 5: 453-8.
62. Irie K, Isaka T, Iwata Y, Yanai Y, Nakamura Y, Koizumi F, et al. Synthesis and biological activities of new conformationally restricted analogues of (-)-indolactam-V: elucidation of the biologically active conformation of the tumor-promoting teleocidins. J Am Chem Soc 1996; 118: 10733-43.
63. Masuda A, Irie K, Nakagawa Y, Ohigashi H. Binding selectivity of conformationally restricted analogues of (-)-indolactam-V to the C1 domains of protein kinase C isozymes. Biosci Biotechnol Biochem 2002; 66: 1615-7.
64. Setterblad N, Onyango I, Pihlgren U, Rask L, Andersson G. The role of protein kinase C signaling in activated DRA transcription. J Immunol 1998; 161: 4819-24.
65. Nakagawa Y, Irie K, Komiya Y, Ohigashi H, Tsuda K. Synthesis, conformation and PKC isozyme surrogate binding of indolinelactam-Vs, new conformationally-restricted analogues of (-)-indolactam-V. Tetrahedron, in press.
66. 2+ and diacylglycerol. Biochem J 2003; 370: 901-12.
67. Quest AFG, Bell RM. The regulatory region of protein kinase Cγ. Studies of phorbol ester binding to individual and combined functional segments expressed as glutathione S-transferase fusion proteins indicate a complex mechanism of regulation by phospholipids, phorbol esters, and divalent cations. J Biol Chem 1994; 269: 20000-12.
68. Endo Y, Takehana S, Ohno M, Driedger PE, Stabel S, Mizutani MY et al. Clarification of the binding mode of teleocidin and benzolactams to the Cys2 domain of protein kinase Cδ by synthesis of hydrophobically modified, teleocidin-mimicking benzolactams and computational docking simulation. J Med Chem 1998; 41: 1476-96.
69. Wang S, Liu M, Lewin NE, Lorenzo PS, Bhattacharrya D, Qiao L, et al. Probing the binding of indolactam-V to protein kinase C through site-directed mutagenesis and computational docking simulations. J Med Chem 1999; 42: 3436-46.
70. Endo Y, Ohno M, Hirano M, Itai A, Shudo K. Synthesis, conformation, and biological activity of teleocidin mimics, benzolactams. A clarification of the conformational flexibility problem in structure-activity studies of teleocidins. J Am Chem Soc 1996; 118: 1841-55.
71. Endo Y, Ohno M, Takehara S, Driedger PA, Stabel S, Shudo K. Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of benzolactams with alkyl substituents at various positions. Chem Pharm Bull 1997; 45: 424-6.
72. Kozikowski AP, Wang S, Ma D, Yao J, Ahmad S, Glazer RI, et al. Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCδ and discovery of an ILV analogue of improved isozyme selectivity. J Med Chem 1997; 40: 1316-26.
73. Kozikowski AP, Ma D, Pang YP, Shum P, Likic V, Mishra PK, et al. Synthesis, molecular modeling, 2-D-NMR, and biological evaluation of ILV mimics as potential modulators of protein kinase C. J Am Chem Soc 1993; 115: 3957-65.
74. Ma D, Wang G, Wang S, Kozikowski AP, Lewin NE, Blumberg PM. Synthesis and protein kinase C binding activity of benzolactam-V7. Bioorg Med Chem Lett 1999; 9: 1371-4.
75. Endo Y, Yamaguchi M, Hirano M, Shudo K. Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of 9-alkylated benzolactams. Chem Pharm Bull 1996; 44: 1138-40.
76. Endo Y, Yokoyama A. Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of 2-alkylated benzolactams. Bioorg Med Chem Lett 2000; 10: 63-6.
77. Ma D, Tang G, Kozikowski AP. Synthesis of 7-susbstituted benzolactam-V8s and their selectivity for protein kinase C isozymes. Org Lett 2002; 4: 2377-80.
78. Ma D, Zhang T, Wang G, Kozikowski AP, Lewin NE, Blumberg PM. Synthesis of 7,8-disubstituted benzolactam-V8 and its binding to protein kinase C. Bioorg Med Chem Lett 2001; 11: 99-101.
79. Nakagawa Y, Irie K, Nakamura Y, Ohigashi H. The amide hydrogen of (-)-indolactam-V and benzolactam-V8's plays a critical role in protein kinase C binding and tumor-promoting activities. Bioorg Med Chem Lett 2001; 11: 723-8.
80. Nakagawa Y, Irie K, Masuda A, Ohigashi H. Synthesis, conformation and PKC isozyme surrogate binding of new lactone analogues of benzolactam-V8s. Tetrahedron 2002; 58: 2101-15.
81. Nakagawa Y, Irie K, Yamanaka N, Ohigashi H, Tsuda K. Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes. Bioorg Med Chem Lett 2003; 13: 3015-19.
82. Kazanietz MG. Novel "nonkinase" phorbol ester receptors: the C1 domain connection. Mol Pharmacol 2002; 61: 759-67.
83. Yang, CF, Kazanietz, MG. Divergence and complexities in DAG signaling: looking beyond PKC. Trends Pharm Sci 2003; 24: 602-8.
84. van Blitterswijk WJ, Houssa B. Properties and functions of diacylglycerol kinases. Cell Signal 2000; 12: 595-605.
85. Kanoh H, Yamada K, Sakane F. Diacylglycerol kinases: emerging down stream regulators in cell signaling systems. J Biochem 2002; 131: 629-33.
86. Ahmed S, Kozma R, Lee J, Montries C, Harden N, Lim L. The cysteine-rich domain of human proteins, neuronal chimaerin, protein kinase C and diacylglycerol kinase binds zinc. Evidence for the involvement of a zinc-dependent structure in phorbol ester binding. Biochem J 1991; 280: 233-41.
87. Sakane F, Kai M, Wada I, Imai S, Kanoh H. The C-terminal part of diacylglycerol kinase α lacking zinc fingers serves as a catalytic domain. Biochem J 1996; 318: 583-90.
88. Kazanietz MG, Wang S, Milne GWA, Lewin NE, Liu HL, Blumberg PM. Residues in the second cysteine-rich region of protein kinase Cδ relavant to phorbol ester binding as revealed by site-directed mutagenesis. J Biol Chem 1995; 270: 21852-9.
89. Shindo M, Irie K, Ohigashi H, Kuriyama M, Saito N. Diacylglycerol kinase γ is one of the specific receptors of tumor-promoting phorbol esters. Biochem Biophys Res Commun 2001; 289: 451-6.
90. Shindo M, Irie K, Masuda A, Ohigashi H, Shirai Y, Miyasaka K, et al. Synthesis and phorbol ester binding of the cysteine-rich domains of diacylglycerol kinase (DGK) isozymes. DGKγ and DGKβ are new targets of tumor-promoting phorbol esters. J Biol Chem 2003; 278: 18448-54.
91. Shirai Y, Segawa S, Kuriyama M, Goto K, Sakai N, Saito N. Subtype-specific translocation of diacylglycerol kinase α and γ and its correlation with protein kinase C. J Biol Chem 2000; 275: 24760-6.
92. Leviton I. Separating fact from fiction: the data behind allergies and side effects caused by penicillins, cephalosporins, and carbapenem antibiotics. Curr Pharm Design 2003; 9(12): 983-8.
93. Wilhelm S and Chien DS. BAY 43-9006: preclinical data. Curr Pharm Design 2002; 8(25): 2255-7.
94. Woolfrey JR and Weston GS. The use of computational methods in the discovery and design of kinase inhibitors. Curr Pharm Design 2002; 8(17):1527-45.